EA201490766A1 - Комбинированная терапия рака яичников - Google Patents

Комбинированная терапия рака яичников

Info

Publication number
EA201490766A1
EA201490766A1 EA201490766A EA201490766A EA201490766A1 EA 201490766 A1 EA201490766 A1 EA 201490766A1 EA 201490766 A EA201490766 A EA 201490766A EA 201490766 A EA201490766 A EA 201490766A EA 201490766 A1 EA201490766 A1 EA 201490766A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ovarian cancer
combined therapy
ylamine
dimethylpropyl
gemcitabine
Prior art date
Application number
EA201490766A
Other languages
English (en)
Other versions
EA026297B1 (ru
Inventor
Эдвард Майкл Чань
Сьюзан Элизабет Пратт
Луис Франк Станкато
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201490766A1 publication Critical patent/EA201490766A1/ru
Publication of EA026297B1 publication Critical patent/EA026297B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В изобретении предложен способ лечения рака яичников у нуждающегося в таком лечении млекопитающего, включающий введение эффективного количества комбинации гемцитабина, цисплатина или карбоплатина, и 5-[2-трет-бутил-5-(4-фторфенил)-1H-имидазол-4-ил]-3-(2,2-диметилпропил)-3H-имидазо[4,5-b]пиридин-2-иламина.
EA201490766A 2011-11-11 2012-10-31 Комбинированная терапия рака яичников EA026297B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558582P 2011-11-11 2011-11-11
PCT/US2012/062634 WO2013070460A1 (en) 2011-11-11 2012-10-31 Combination therapy for ovarian cancer

Publications (2)

Publication Number Publication Date
EA201490766A1 true EA201490766A1 (ru) 2014-08-29
EA026297B1 EA026297B1 (ru) 2017-03-31

Family

ID=47146746

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490766A EA026297B1 (ru) 2011-11-11 2012-10-31 Комбинированная терапия рака яичников

Country Status (30)

Country Link
US (1) US9844529B2 (ru)
EP (1) EP2780011B1 (ru)
JP (1) JP6055481B2 (ru)
KR (1) KR101647569B1 (ru)
CN (1) CN103917233B (ru)
AP (1) AP3881A (ru)
AU (1) AU2012336154B2 (ru)
BR (1) BR112014011197A2 (ru)
CA (1) CA2850559C (ru)
CR (1) CR20140211A (ru)
CY (1) CY1120315T1 (ru)
DK (1) DK2780011T3 (ru)
DO (1) DOP2014000100A (ru)
EA (1) EA026297B1 (ru)
ES (1) ES2671730T3 (ru)
HR (1) HRP20180875T1 (ru)
HU (1) HUE037928T2 (ru)
IL (1) IL232479A0 (ru)
LT (1) LT2780011T (ru)
ME (1) ME03035B (ru)
MX (1) MX2014005698A (ru)
MY (1) MY168927A (ru)
PL (1) PL2780011T3 (ru)
PT (1) PT2780011T (ru)
RS (1) RS57256B1 (ru)
SG (1) SG11201401795XA (ru)
SI (1) SI2780011T1 (ru)
TN (1) TN2014000150A1 (ru)
WO (1) WO2013070460A1 (ru)
ZA (1) ZA201403159B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016013027A (es) 2014-04-04 2017-05-23 Del Mar Pharmaceuticals Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533360A (ja) * 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための3−ヘテロアリーリデニル−2−インドリノン化合物
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors

Also Published As

Publication number Publication date
BR112014011197A2 (pt) 2017-04-25
EP2780011A1 (en) 2014-09-24
US20140302174A1 (en) 2014-10-09
AP2014007631A0 (en) 2014-05-31
CR20140211A (es) 2014-06-20
AU2012336154A1 (en) 2014-04-17
HUE037928T2 (hu) 2018-09-28
US9844529B2 (en) 2017-12-19
MX2014005698A (es) 2014-08-21
ES2671730T3 (es) 2018-06-08
CA2850559C (en) 2016-11-29
AP3881A (en) 2016-10-31
RS57256B1 (sr) 2018-08-31
KR20140083010A (ko) 2014-07-03
SG11201401795XA (en) 2014-09-26
KR101647569B1 (ko) 2016-08-10
CN103917233B (zh) 2018-11-16
HRP20180875T1 (hr) 2018-07-13
CA2850559A1 (en) 2013-05-16
CN103917233A (zh) 2014-07-09
NZ623622A (en) 2015-07-31
MY168927A (en) 2019-01-08
DOP2014000100A (es) 2014-06-30
SI2780011T1 (en) 2018-07-31
CY1120315T1 (el) 2019-07-10
EP2780011B1 (en) 2018-04-11
ME03035B (me) 2018-10-20
ZA201403159B (en) 2017-11-29
EA026297B1 (ru) 2017-03-31
DK2780011T3 (en) 2018-05-28
WO2013070460A1 (en) 2013-05-16
AU2012336154B2 (en) 2017-01-12
PT2780011T (pt) 2018-05-14
PL2780011T3 (pl) 2018-08-31
JP6055481B2 (ja) 2016-12-27
TN2014000150A1 (en) 2015-09-30
JP2014533270A (ja) 2014-12-11
IL232479A0 (en) 2014-06-30
LT2780011T (lt) 2018-05-10

Similar Documents

Publication Publication Date Title
MX2017016491A (es) Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
MY162903A (en) Methods of treatment of pancreatic cancer
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
BR112015016681A2 (pt) métodos de tratamento de câncer pancreático
EA202092187A1 (ru) Способы лечения эпителиоидно-клеточных опухолей
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112015007184A2 (pt) combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
BR112014028017A2 (pt) composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror
MX2017002852A (es) Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.
EA201792509A1 (ru) Лечение рака
BR112017003571A2 (pt) terapia combinada
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
CY1120315T1 (el) Συνδυαστικη θεραπεια για καρκινο των ωοθηκων
MX2019004804A (es) Tratamiento para el prurigo nodula.
EA201491581A1 (ru) Везикулярные композиции
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU